Arkolith/Insider Trading/SABS/Form 4

Reich Samuel J

Executive Chairman, DirectorSAB Biotherapeutics, Inc. (SABS) · full profile →Form 4 · filed Nov 30, 2023
Net Buying
Open-Market Buys
$10K
Open-Market Sells
$0
Net Open-Market Flow
$10K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 29, 2023Buy(P)11K$0.89$10K219K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-23-066901) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML